Media headlines about Axsome Therapeutics (NASDAQ:AXSM) have been trending positive recently, according to Accern Sentiment. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Axsome Therapeutics earned a media sentiment score of 0.27 on Accern’s scale. Accern also gave news headlines about the company an impact score of 47.5759490975231 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the headlines that may have impacted Accern Sentiment’s scoring:
- Axsome Therapeutics to Present at 17th Annual Needham … – EconoTimes (econotimes.com)
- Hot Stock to Track – Axsome Therapeutics, Inc. (NASDAQ: AXSM) – The Investor Guide (wallstreetnews24.com)
- Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Hot Stock’s Watch List – Nasdaq Journal (nasdaqjournal.com)
- Axsome Therapeutics (AXSM) Downgraded by Zacks Investment Research to Sell (americanbankingnews.com)
- Axsome Therapeutics Presents Scientific Rationale for the Development of AXS-05 at the 20th Annual Meeting of the … – GlobeNewswire (press release) (globenewswire.com)
Shares of Axsome Therapeutics stock traded down $0.05 during mid-day trading on Monday, hitting $2.65. 126,292 shares of the stock traded hands, compared to its average volume of 433,104. The company has a debt-to-equity ratio of 0.40, a quick ratio of 2.90 and a current ratio of 2.90. Axsome Therapeutics has a 12 month low of $2.45 and a 12 month high of $6.45. The stock has a market cap of $68.83, a price-to-earnings ratio of -2.05 and a beta of -0.20.
Several brokerages have recently issued reports on AXSM. Zacks Investment Research lowered shares of Axsome Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, March 13th. ValuEngine upgraded shares of Axsome Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. Finally, Cantor Fitzgerald set a $13.00 price target on shares of Axsome Therapeutics and gave the stock a “buy” rating in a research note on Friday, December 1st. Two equities research analysts have rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $16.90.
ILLEGAL ACTIVITY WARNING: “Axsome Therapeutics (AXSM) Receiving Favorable Press Coverage, Study Shows” was first reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/3278863/axsome-therapeutics-axsm-receiving-favorable-press-coverage-study-shows.html.
About Axsome Therapeutics
Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain.
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.